1.   World Health Organization (WHO). Human papillomavirus and related diseases report. http://www.hpvcentre.net/statistics/reports/XWX.pdf. Published 18 December 2014.Accessed 27 March 2015.

2.   World Health Organization (WHO). The current status of development of prophylactic vaccines against human papillomavirus infection. Report of a technical meeting, Geneva, 16–18 February 1999. Geneva, Switzerland: World Health Organization; 1999. http://whqlibdoc.who.int/hq/1999/WHO_V&B_99.04.pdf. Accessed 24 February 2015.

3.   World Health Organization (WHO). Executive summary: the state of world health. http://www.who.int/whr/1995/media_centre/executive_summary1/en/print.html.
Accessed 24 February 2015.

4.   Centers for Disease Control and Prevention (CDC). Genital HPV infection—CDC fact sheet. www.cdc.gov/std/hpv/hpv-factsheet-march-2014.pdf. Updated 23 January 2014. Accessed 24 February 2015.

5.   Centers for Disease Control and Prevention (CDC). Human papillomavirus. In: Atkinson W, Hamborsky J, Stanton A, et al, eds. Epidemiology and Prevention of Vaccine-Preventable Diseases. 12th rev ed. 2nd printing. Washington, DC: Public Health Foundation; 2012:139–150.

6.   Koutsky L. Epidemiology of genital human papillomavirus infection. Am J Med. 1997;102(5A):3–8.

7.   de Sanjose S, Alemany L, Ordi J, et al. Worldwide human papillomavirus genotype attribution in over 2000 cases of intraepithelial and invasive lesions of the vulva.
Eur J Cancer. 2013;49(16):3450–3461.

8.   Alemany L, Saunier M, Tinoco L, et al. Large contribution of human papillomavirus in vaginal neoplastic lesions: a worldwide study in 597 samples. Eur J Cancer. 2014;50(16):2846–2854.

9.   Alemany L, Saunier M, Alvarado-Cabrero I, et al. Human papillomavirus DNA prevalence and type distribution in anal carcinomas worldwide. Int J Cancer.

10. Guan P, Howell-Jones R, Li N, et al. Human papillomavirus types in 115,789 HPV-positive women: a meta-analysis from cervical infection to cancer. Int J Cancer. 2012;131(10):2349–2359.

11. Cervarix® alkalmazási előírás

12. de Sanjose S, Quint WGV, Alemany L, et a l. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study.
Lancet Oncol. 2010;11(11):1048–1056.

13. Joura EA, Ault KA, Bosch FX, et al. Attribution of 12 high-risk human papillomavirus genotypes to infection and cervical disease. Cancer Epidemiol Biomarkers Prev. 2014;23(10):1997–200.

14. Garland SM, Steben M, Sings HL, et al. Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine. J Infect Dis. 2009;199(6):805–814.

15. Silgard® alkalmazási előírás

16. GARDASIL 9® alkalmazási előírás

17. Tjalma WA, et al. Differences in human papillomavirus type distribution in high-grade cervical intraepithelial neoplasia and invasive cervical cancer in Europe. Int. J. Cancer: 132, 854–867 (2013)